A novel prognostic signature for hepatocellular carcinoma based on SUMOylation-related genes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 07 2023
11 07 2023
Historique:
received:
11
03
2022
accepted:
05
07
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
SUMOylation (SUMO modification) has been confirmed to play an essential role in the progression of various malignancies. As the value of SUMOylation-related genes (SRGs) in prognosis prediction of hepatocellular carcinoma (HCC) has not been explored, we aim to construct an HCC SRGs signature. RNA sequencing was utilized to identify differentially expressed SRGs. The 87 identified genes were used in Univariate Cox regression analysis and the Least Absolute Shrinkage and Selection Operator (LASSO) analysis to build a signature. The accuracy of the model was validated by the ICGC and GEO datasets. The GSEA revealed that the risk score was associated with common cancer-related pathways. The ssGSEA showed that NK cells in the high-risk group were significantly reduced. The sensitivities of anti-cancer drugs confirmed the sensitivity of the high-risk group to sorafenib was lower. Further, our cohort showed that risk scores were correlated with advanced grade and vascular invasion (VI). Finally, the results of H&E staining and immunohistochemistry of Ki67 showed that higher-risk patients are more malignant.
Identifiants
pubmed: 37433803
doi: 10.1038/s41598-023-38197-4
pii: 10.1038/s41598-023-38197-4
pmc: PMC10336129
doi:
Substances chimiques
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11233Informations de copyright
© 2023. The Author(s).
Références
Sung, H., Ferlay, J., Siegel, R. L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. (2021) (undefined).
Ryu, T. et al. Actual 10-year survival after surgical microwave ablation for hepatocellular carcinoma: A single center experience in Japan. Ann. Surg. Oncol. 26(12), 4126–4133 (2019).
doi: 10.1245/s10434-019-07646-8
pubmed: 31359277
Zheng, J. et al. Actual 10-year survivors after resection of hepatocellular carcinoma. Ann. Surg. Oncol. 24(5), 1358–1366 (2017).
doi: 10.1245/s10434-016-5713-2
pubmed: 27921192
Alejandro, F., María, R. & Jordi, B. Hepatocellular carcinoma. Lancet 391, 1301–1314 (2018).
doi: 10.1016/S0140-6736(18)30010-2
Xie, Y. et al. Immunotherapy for hepatocellular carcinoma: Current advances and future expectations. J. Immunol. Res. 2018, 8740976 (2018).
doi: 10.1155/2018/8740976
pubmed: 29785403
pmcid: 5896259
Wang, D. et al. Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges. World J. Gastrointest. Surg. 15(4), 544–552 (2023).
doi: 10.4240/wjgs.v15.i4.544
pubmed: 37206072
pmcid: 10190723
Lim, K. C. et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann. Surg. 254, 108–113 (2011).
doi: 10.1097/SLA.0b013e31821ad884
pubmed: 21527845
Chang, H.-M. & Yeh Edward, T. H. SUMO: From bench to bedside. Physiol. Rev. 100, 1599–1619 (2020).
doi: 10.1152/physrev.00025.2019
pubmed: 32666886
pmcid: 7717128
Gareau, J. R. & Lima, C. D. The SUMO pathway: Emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861–871 (2010).
doi: 10.1038/nrm3011
pubmed: 21102611
pmcid: 3079294
Seeler, J.-S. & Dejean, A. SUMO and the robustness of cancer. Nat. Rev. Cancer 17, 184–197 (2017).
doi: 10.1038/nrc.2016.143
pubmed: 28134258
Boulanger, M. et al. The SUMO pathway in hematomalignancies and their response to therapies. Int. J. Mol. Sci. 20, 3895 (2019).
doi: 10.3390/ijms20163895
pubmed: 31405039
pmcid: 6721055
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 68(6), 394–424 (2018).
doi: 10.3322/caac.21492
Human Protein Atlas Bogachek Maria, V., Park Jung, M., De Andrade James, P. et al. Inhibiting the SUMO pathway represses the cancer stem cell population in breast and colorectal carcinomas. Stem Cell Rep. 7, 1140–1151 (2016).
He, X. et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat. Chem. Biol. 13, 1164–1171 (2017).
doi: 10.1038/nchembio.2463
pubmed: 28892090
Flotho, A. & Melchior, F. Sumoylation: A regulatory protein modification in health and disease. Annu. Rev. Biochem. 82, 357–385 (2013).
doi: 10.1146/annurev-biochem-061909-093311
pubmed: 23746258
Yu, B. et al. Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc. Natl. Acad. Sci. U. S. A. 112, E1724–E1733 (2015).
doi: 10.1073/pnas.1415569112
pubmed: 25805818
pmcid: 4394293
Chang, H. M. & Yeh, E. T. H. SUMO: From bench to bedside. Physiol. Rev. 100(4), 1599–1619 (2020).
doi: 10.1152/physrev.00025.2019
pubmed: 32666886
pmcid: 7717128
Beltrao, P., Bork, P., Krogan, N. J. & van Noort, V. Evolution and functional cross-talk of protein post-translational modifications. Mol. Syst. Biol. 22(9), 714 (2013).
doi: 10.1002/msb.201304521
Liu, Y. et al. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation. Open Med. (Wars). 17(1), 1183–1202 (2022).
doi: 10.1515/med-2022-0510
pubmed: 35859792
pmcid: 9263891
Jeon, T. et al. Silencing CDCA8 suppresses hepatocellular carcinoma growth and stemness via restoration of ATF3 tumor suppressor and inactivation of AKT/β-catenin signaling. Cancers (Basel). 13(5), 1055 (2021).
doi: 10.3390/cancers13051055
pubmed: 33801424
pmcid: 7958635
Klein Ulf, R. & Nigg Erich, A. SUMO-dependent regulation of centrin-2. J. Cell Sci. 122, 3312–3321 (2009).
doi: 10.1242/jcs.050245
pubmed: 19706679
Mao, J. et al. CBX2 regulates proliferation and apoptosis via the phosphorylation of YAP in hepatocellular carcinoma. J. Cancer 10, 2706–2719 (2019).
doi: 10.7150/jca.31845
pubmed: 31258779
pmcid: 6584921
Hsieh, C.-H. et al. Vascular invasion affects survival in early hepatocellular carcinoma. Mol. Clin. Oncol. 3, 252–256 (2015).
doi: 10.3892/mco.2014.420
pubmed: 25469305
Sumie, S. et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann. Surg. Oncol. 21, 1002–1009 (2014).
doi: 10.1245/s10434-013-3376-9
pubmed: 24254204
Pawlik, T. M. et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch. Surg. 140, 450–458 (2005).
doi: 10.1001/archsurg.140.5.450
pubmed: 15897440
Carmen, D.-B. et al. Targeting mitosis in cancer: emerging strategies. Mol Cell 60, 524–536 (2015).
doi: 10.1016/j.molcel.2015.11.006
Liu, J. et al. Mesencephalic astrocyte-derived neurotrophic factor inhibits liver cancer through small ubiquitin-related modifier (SUMO)ylation-related suppression of NF-κB/snail signaling pathway and epithelial–mesenchymal transition. Hepatology 71, 1262–1278 (2020).
doi: 10.1002/hep.30917
pubmed: 31469428
Justus, C. R., Sanderlin, E. J. & Yang, L. V. Molecularconnections between cancer cell metabolism and the tumor micro-environment. Int. J. Mol. Sci. 16(5), 11055–11086 (2015).
doi: 10.3390/ijms160511055
pubmed: 25988385
pmcid: 4463690
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12(4), 239–252 (2012).
doi: 10.1038/nri3174
pubmed: 22437937
pmcid: 5161343
Kumar, S. et al. Targeting pancreatic cancer by TAK-981: A SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut 71, 2266–2283 (2022).
doi: 10.1136/gutjnl-2021-324834
pubmed: 35074907
Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6(11), 836–848 (2006).
doi: 10.1038/nri1961
pubmed: 17063185
Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
pubmed: 16199517
pmcid: 1239896
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
doi: 10.1093/nar/gkv007
pubmed: 25605792
pmcid: 4402510
Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12), 1572–1573 (2010).
doi: 10.1093/bioinformatics/btq170
pubmed: 20427518
pmcid: 2881355
Thul, P. J. & Lindskog, C. The human protein atlas: A spatial map of the human proteome. Protein Sci. 27(1), 233–244 (2018).
doi: 10.1002/pro.3307
pubmed: 28940711
Combescure, C., Perneger, T. V., Weber, D. C., Daurès, J. P. & Foucher, Y. Prognostic ROC curves a method for representing the overall discriminative capacity of binary markers with right-censored time-to-event endpoints. Epidemiology 25(1), 103–109 (2014).
doi: 10.1097/EDE.0000000000000004
pubmed: 24240658
Rooney, M. S. et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1–2), 48–61 (2015).
doi: 10.1016/j.cell.2014.12.033
pubmed: 25594174
pmcid: 4856474
Geeleher, P., Cox, N. & Huang, R. S. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 9, e107468 (2014).
doi: 10.1371/journal.pone.0107468
pubmed: 25229481
pmcid: 4167990